2007 Apr;12(2):126-9. doi: 10.1111/j.1440-1797.2006.00762.x. alfa and 200 mcg every 2 weeks for darbepoetin alfa. Initiate Aranesp treatment when the hemoglobin level is less than 10 g/dL. Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. On May 15, 2018, the Food and Drug Administration approved Retacrit (epoetin alfa-epbx, Hospira Inc., a subsidiary of Pfizer Inc.) as a biosimilar to Epogen/Procrit (epoetin alfa, Amgen Inc.) for . 2017 Jun 30;4:2054358117716461. doi: 10.1177/2054358117716461. endobj
If the hemoglobin level approaches or exceeds 12 g/dL, reduce or interrupt the dose of Aranesp. Darbepoetin alfa (5 N-linked
Epogen is used in the dialysis area at CCF.
Erythropoiesis-stimulating agents (epoetin alfa, beta, theta and zeta 2009 Oct;2(5):347-53. doi: 10.1093/ndtplus/sfp097. levels, and to improve quality of life. In the event that ARDS occurs, Neulasta should be discontinued and/or withheld until resolution of ARDS and patients should receive appropriate medical management for this condition. 4. Supplied Injection, powder for reconstitution: 5 mg, INDICATIONS AND USAGE Neulasta is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. 5,o_2&+PA1xRAag(sRVt?jN)r!ba,cKc$Z`6@5&ql~d:P /bc
yh{fM"fCCmF6TBxgE= Vue-#x4Bi8&ZC; Clipboard, Search History, and several other advanced features are temporarily unavailable. Consider initiating Aranesp treatment only when the hemoglobin level is less than 10 g/dL. endstream
endobj
336 0 obj
<>stream
Each 1 mL single-dose vial of 2,000, 3,000, 4,000, 10,000, and 40,000 Units of epoetin alfa-epbx injection contains 0.5 mg of phenylalanine.
RETACRIT Dosage and Administration (epoetin alfa-epbx) Correct or exclude other causes of anemia (e.g., vitamin deficiency, metabolic or chronic inflammatory conditions, bleeding, etc.) hbbd```b``IA$/f?W$_d6X&LE@${`lktfu` : 6C(XlB3XDD&iMt#K/X=(IW? l Preclinical trials have shown that mature megakaryocytes which develop during in vivo treatment with Neumega are ultrastructurally normal. %
Beneficial dose conversion after switching from higher doses of shorter-acting erythropoiesis-stimulating agents to C.E.R.A in CKD patients in clinical practice: MINERVA Study. Discontinue treatment with oprelvekin >/= 2 days before starting the next planned cycle of chemotherapy.
PDF Highlights of Prescribing Information ----------------------- Dosage in two ways: 1) Hgb levels > 12 g/dL or 2) an increase
chemotherapy. Generic name: DARBEPOETIN ALFA 10ug in 0.4mL
Aranesp (darbepoetin alfa) | Dosing Considerations Before sharing sensitive information, make sure you're on a federal government site. Before sharing sensitive information, make sure you're on a federal government site. >/@tCh;6|{rf9V8&Wb~%l7JNCcoi AkrJ.ttbdq5QSu+r|0&OhF]{.r!r
SN:]AW&g{auwi(D)Si'(EK 9P$a8d_R/au&tIk=[A'"Uh
5E~"{dC4dMs/*e?&Io}a\d05zVJ)~OL:MK'tiM>)r4zoBp`Vju`'78f4*q-PFa_,R2(r\?ASM^B6DT&s+IfUSqS6H5l~b)lMx:'j_sT[.q"ju g/8f5>tWw]}vAQNK0:
st3pYBMf7m\tHC6l#C(!%J[l6(d/$Apx>GW mo^6*{INX%!ZuH@=_c Committee will be exploring other patient populations for this
PRCA has also been reported in patients receiving ESAs for anemia related to hepatitis C treatment (an indication for which RETACRIT is not approved). 1.3 Patients with Cancer Undergoing Bone Marrow Transplantation ZARXIO is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae e.g.febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation [see Clinical Studies (14.3)]. Unauthorized use of these marks is strictly prohibited. Administer supplemental iron therapy when serum ferritin is less than 100 mcg/L or when serum transferrin saturation is less than 20%.
Conversion - Epoetin alfa (Procrit) to Darbepoetin | GrepMed <>/Filter/FlateDecode/ID[<6A376E50FA41294D8BDE0DC442E05AF8>]/Index[1022 100]/Info 1021 0 R/Length 147/Prev 333934/Root 1023 0 R/Size 1122/Type/XRef/W[1 3 1]>>stream
Endogenous G-CSF is a lineage-specific colony-stimulating factor that is produced by monocytes fibroblasts, and endothelial cells. Epogen (Amgen), another brand name for epoetin
"9hu2,yUHZC]r}P(j 5{O$Mv$5O6
r~_RMN: 2YSkk.g_GCUswyDxD5m#):`1#V0O_>$gpz~Q5I^D6u'R52O Ou>dteJB* The optimal timing and duration of growth factor stimulation has not been determined. Dosage adjustment: Goal: Dose should be adjusted to achieve and maintain a target hemoglobin not to exceed 12 g/dL.
4 0 obj
In addition, Hgb levels were
overall. During the first several months following initiation of RETACRIT, monitor patients closely for premonitory neurologic symptoms. Questions regarding
Methods: All in-centre haemodialysis patients (n = 60) were converted from an existing subcutaneous epoetin alfa regimen to weekly intravenous darbepoetin alfa. . Slowly push the plunger up to force the air bubbles out of the syringe. MeSH Overall, in
chemotherapy, MDS or MF, continued therapy) Please provide a hemoglobin level (g/dL) for your patient taken within the first 12 weeks of therapy with epoetin and include the date the lab was drawn. To report an adverse event, please call 1-800-438-1985. The U.S. Food and Drug Administration today approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic . and approved an automatic therapeutic interchange to darbepoetin
Biological products are generally derived from a living organism and can come from many sources, such as humans, animals, microorganisms or yeast. Do not dilute. M(aOf}c^gw+&=s=O{+h5ACmVA;8*=vSO`8dmD}a"'3L
DMr7GwG 3\\q'z .MreQlX`DWxxxnU@!TUrTng_wAMc`0N[P Si)i+j(1A%@xaB&Zx03\'O.h` &!T6. 0*ET*LQjH!z!6G OsI`~ We comply with the HONcode standard for trustworthy health information.
PDF Highlights of Prescribing Information ------------------dosage and Retacrit (epoetin alfa-epbx) Biosimilar Formulary Preferred Use Retacrit Nephrology (Carlton).
Product Information and Dosing | Mircera 150 units/kg SC 3 times/week or 40,000 units once weekly. Following initiation of therapy and after each dose adjustment, monitor hemoglobin weekly until the hemoglobin level is stable and sufficient to minimize the need for RBC transfusion. Conversion from Epoetin alfa to Aranesp in patients with CKD on dialysis. Inadequate response: Hemoglobin increases <1 g/dL over 4 weeks and iron stores are adequate: Increase by ~25% of the previous dose; increases should not be made more frequently than once monthly. official website and that any information you provide is encrypted Aranesp is a medicine used to treat anaemia (low red blood cell counts) that is causing symptoms. Darbepoetin alfa. However, this may result in the over treatment of uraemic anaemia. 1.4 Patients Undergoing Autologous Peripheral Blood Progenitor Cell Collection and Therapy ZARXIO is indicated for the mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis [see Clinical Studies (14.4)]. Previous dosage of epoetin alfa: 11,000-17,999 units/week,then darbepoetin alfa dosage: 40 mcg/week. OMONTYS has not been shown to improve symptoms, physical functioning or health-related quality of life. Avoid frequent dose adjustments. Martnez Castelao A, Reyes A, Valds F, Otero A, Lpez de Novales E, Pallard L, Tabernero JM, Hernndez Jaras J, Llads F. Brunkhorst R, Bommer J, Braun J, Haag-Weber M, Gill C, Wagner J, Wagener T; German Aranesp Study Group. Monitoring Parameters Complete blood count and platelet count should be obtained prior to chemotherapy. Based on data from this CCHS DUE, darbepoetin alfa and
RETACRIT (epoetin alfa-epbx) Dosing Info | Safety Info - Pfizer pro Medically reviewed by Drugs.com. endstream adverse event to Retacrit (epoetin alfa), and the adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information; OR For patients that are currently on treatment with Aranesp (darbepoetin alfa) they can remain on Administer supplemental iron therapy when serum ferritin is less than 100 mcg/L or when serum transferrin saturation is less than 20%. Neulasta should be permanently discontinued in patients with serious allergic reactions.
The needle cover of the prefilled syringe contains dry natural rubber (a derivative of latex), which may cause allergic reactions. The assessment will also assess whether the reviewed drugs are likely to be considered good value for money for the NHS. Nephrol Dial Transplant. INDICATIONS AND USAGE: 1.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy ZARXIO is indicated to decrease the incidence of infection as manifested by febrile neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever [see Clinical Studies (14.1)]. Patient Name_____ NKC#_____ Revised 01/14/2016 Page 1 of 4. Drug class: recombinant human erythropoietins, Aranesp (Darbepoetin Alfa Prefilled Syringes), Anemia Associated with Chronic Renal Failure, If hemoglobin exceeds a level needed to avoid RBC transfusion, If hemoglobin increases by less than 1 g/dL. The dose of MIRCERA , given as a single intravenous or subcutaneous injection, should be based on the total weekly ESA dose at the time of . See full prescribing information for RETACRIT. Coverage Limitations Treatment with Darbepoetin alfa (Aranesp), Epoetin alfa (Procrit), Epoetin alfa (Epogen), and Epoetin alfa-epbx (Retacrit) is not considered medically necessary for members with the following concomitant conditions: lNY0?j/0a6d%J1\3\qdS@*_gy{sl?!H^]ibQ'_(%`lI$5.r U ?Xz:sf;{@(eHB Excessive response: Hemoglobin increases >1 g/dL in any 2-week period: Decrease dose Hemoglobin increases and approaches the target value of 12 g/dL: Decrease weekly dosage by ~25%. (CKD) patients, darbepoetin alfa administered intravenously has
epoetin alfa and darbepoetin alfa for the management of CIA. x]Y8~w&*qq8g91YJUjUr2$u UuKf"3e&U+Wq&0Y The approval was based on comparisons of extensive structural and functional product characterization, animal data, human pharmacokinetic and pharmacodynamic data, clinical immunogenicity between Retacrit and U.S.-licensed Epogen/Procrit demonstrating that Retacrit is highly similar to US-licensed Epogen/Procrit and that there are no clinically meaningful differences between the products. alfa. RETACRIT is contraindicated in patients with: RETACRIT from multiple-dose vials contains benzyl alcohol and is contraindicated in: INCREASED MORTALITY, MYOCARDIAL INFARCTION, STROKE, AND THROMBOEMBOLISM, INCREASED MORTALITY AND/OR INCREASED RISK OF TUMOR PROGRESSION OR RECURRENCE IN PATIENTS WITH CANCER, LACK OR LOSS OF HEMOGLOBIN RESPONSE TO RETACRIT, RISK OF SERIOUS ADVERSE REACTIONS DUE TO BENZYL ALCOHOL PRESERVATIVE, ANEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE, ANEMIA DUE TO CHEMOTHERAPY IN PATIENTS WITH CANCER, ANEMIA DUE TO ZIDOVUDINE IN PATIENTS WITH HIV INFECTION, Recommended dosing for adults and children with chronic kidney disease (CKD), The recommended starting dose for adult patients is 50 to 100 Units/kg 3 times weekly intravenously (IV) or subcutaneously (SC). Retacrit has not been shown to be interchangeable with U.S.-licensed Epogen/Procrit. Note: In patients receiving epoetin alfa 2-3 times per week, darbepoetin alfa is administered once weekly.In patients who are receiving epoetin alfa once weekly, darbepoetin should be administered once every 2 weeks. SPLENIC RUPTURE, IN SOME CASES RESULTING IN DEATH, HAS ALSO BEEN ASSOCIATED WITH FILGRASTIM, THE PARENT COMPOUND OF NEULASTA. number of patients receiving transfusions, to increase hemoglobin
duration of therapy was 13.2 weeks and 13.6 weeks in the epoetin
RETACRIT multiple-dose vials contain 8.5 mg of benzyl alcohol per mL. startxref Use the lowest dose of Aranesp necessary to avoid RBC transfusions. Conversion from Epoetin alfa or Darbepoetin alfa to MIRCERA MIRCERA can be administered once every 2 weeks or once monthly to patients whose hemoglobin has been stabilized by treatment with an ESA. Bonafont X, Bock A, Carter D, Brunkhorst R, Carrera F, Iskedjian M, Molemans B, Dehmel B, Robbins S. NDT Plus. <> The IV route is recommended for patients on hemodialysis, For adult patients with CKD not on dialysis, The recommended starting dose for adult patients is 50 to 100 Units/kg 3 times weekly IV or SC, The recommended starting dose for pediatric patients (ages 1 month or older) is 50 Units/kg 3 times weekly IV or SC, Recommended dosing for patients with HIV treated with zidovudine, The recommended starting dose in adults is 100 Units/kg as an IV or SC injection 3 times per week, If hemoglobin does not increase after 8 weeks of therapy, increase RETACRIT dose by approximately 50 to 100 Units/kg at 4- to 8-week intervals until hemoglobin reaches a level needed to avoid red blood cell (RBC) transfusions or 300 Units/kg, Recommended starting dose for adults and children undergoing cancer chemotherapy*, 150 Units/kg SC 3 times per week until completion of a chemotherapy course, or, 40,000 Units SC weekly until completion of a chemotherapy course, 600 Units/kg IV weekly until completion of a chemotherapy course. The minimum amount of benzyl alcohol at which serious adverse reactions may occur is not known, Phenylalanine can be harmful to patients with phenylketonuria (PKU). Vol. July/August 2004, Return to
RETACRIT single-dose vials contain phenylalanine, a component of aspartame. The implementation date for the interchange program is October 11, 2004. 4 x previous weekly epoetin alfa dose (Units)/125. In cancer patients, erythropoietic agents, including
Safety and Efficacy: Currently available data indicate that darbepoetin
<>>>
PDF All Orders Must Be Marked in Ink With a Checkmark to Be Active. - Ohsu Please review the latest applicable package insert for additional information and possible updates. Before prescribing RETACRIT single-dose vials to a patient with PKU, consider the combined daily amount of phenylalanine from all sources, including RETACRIT, Patients may require adjustments in their dialysis prescriptions after initiation of RETACRIT. All Rights Reserved. U qjRO6nY>++xsR _:b*v fzMg918}jS\0^$ i~OG3!tRG`T(b>L&PeRj\L,F#f09w6aCN
$l-FRW+>U0pPhRc/N
R5P-S&C>yxCDL{d^Nij:t5k!_ybecbXharWMmIAS|F7bmM+"qJz)!Yt!V\pz%6aE0oi4ciwy6d" Hypertension: Control hypertension prior to initiating and during treatment with OMONTYS. 11 in the epoetin alfa-treated group and 7 in the darbepoetin alfa-treated
0 Careers. The recommended starting dose is 0.45 mcg/kg body weight intravenously or subcutaneously given once at four week intervals as appropriate. 2 0 obj
Patient treatments were converted from subcutaneous epoetin alfa to weekly, intravenous darbepoetin alfa at month 0, at a conversion dose of 200 units epoetin alfa to 1 microg darbepoetin. Neumega is not indicated following myeloablative chemotherapy (see package insert for WARNINGS, Increased Toxicity Following Myeloablative Therapy). transfusions, and iron studies. epoetin theta (Eporatio [Teva UK]), epoetin zeta (Retacrit [Hospira UK]), and . Non-hematopoietic pathologic changes observed in animals include fibrosis of tendons and joint capsules, periosteal thickening, papilledema, and embryotoxicity. If severe anemia and low reticulocyte count develop during treatment with RETACRIT, withhold RETACRIT and evaluate patients for neutralizing antibodies to erythropoietin. Overall, only 10.5% of patients had iron studies before erythropoietin
half-life of 8.5 hours.
Anemia Hard Choices: Comparing Procrit vs Aranesp : Oncology Times - LWW